Latest Competition News

Imugene’s Phase 1b trial of azer-cel, an off-the-shelf CD19 CAR T therapy, reports a 57% complete response rate in heavily pretreated diffuse large B-cell lymphoma patients, signaling a promising new option in a challenging cancer landscape.

Charter Hall Retail REIT reported a 3.0% same property net property income growth and a stable 98.7% occupancy rate in its 2025 half-year results, while integrating the Hotel Property Investments acquisition to enhance future income growth.

AMP Limited’s FY24 Data Pack outlines a solid underlying profit performance despite headwinds, with key insights into its banking, platform, and wealth management divisions.

GQG Partners delivered robust full-year 2024 results, marked by a 26.9% increase in funds under management and nearly 47% growth in net revenue, underpinned by strong investment performance and strategic initiatives including Private Capital Solutions and a new Abu Dhabi office.

GQG Partners reported a stellar 2024 with net inflows doubling to US$20.2 billion and funds under management climbing nearly 27%, underpinning strong revenue and earnings growth. The firm also expanded its dividend payout range, signaling confidence in future capital management.

GQG Partners Inc. reported strong financial results for 2024, with significant increases in revenue, net income, and funds under management, alongside a raised dividend and strategic moves including the deconsolidation of its PCS Master Fund.

AVITA Medical reported a strong 30% increase in Q4 2024 commercial revenue and amended its credit agreement with OrbiMed to adjust revenue covenants through 2026. The company is poised for significant growth with new product rollouts and expects profitability by year-end 2025.

BPM Minerals has commenced a significant 6,000m aircore drilling program at its Claw Gold Project in Western Australia, aiming to extend known gold mineralisation along an 8km corridor adjacent to Capricorn Metals' Mount Gibson Gold Project.

Civmec Limited reports solid first-half FY25 results with revenue growth and a stable dividend, while navigating margin pressures and advancing strategic projects.

Cochlear Limited posted a 5% increase in sales revenue to $1.17 billion for the half year ended December 2024, driven by strong cochlear and acoustic implant growth despite a decline in Services revenue. The company anticipates FY25 underlying net profit at the lower end of guidance amid increased cloud investments and prepares for new product launches.

Cochlear Limited has announced a fully franked dividend of AUD 2.15 per share for the six months ending December 2024, payable in multiple currencies on April 14, 2025.

Pure Foods Tasmania Limited (ASX: PFT) will recommence trading on the ASX from 14 February 2025 following the lifting of its suspension after submitting reissued financial statements with an unqualified audit opinion.